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Mitochondrial dysfunctionMitochondrial dysfunction and synaptic damage have beendescribed as early events in Alzheimer's disease (AD)
pathogenesis. Recent research using AD postmortem brains, and AD mouse and cell models revealed that amy-
loid beta (Aβ) and tau hyperphosphorylation are involved inmitochondrial dysfunction and synaptic damage in
AD. Further, recent research also revealed that the protein levels of mitochondrial outer membrane protein,
voltage-dependent anion channel 1 (VDAC1), are elevated in the affected regions of AD postmortem brains
and cortical tissues from APP transgenic mice. In addition, emerging research using AD postmortem brains and
ADmousemodels revealed that VDAC1 is linked to Aβ and phosphorylated tau, blocks themitochondrial perme-
ability transition (MPT) pores, disrupts the transport of mitochondrial proteins and metabolites, impairs gating
of VDAC, and causes defects in oxidative phosphorylation, leading to mitochondrial dysfunction in AD neurons.
The purpose of this article is to review research that has investigated the relationship between VDAC1 and the
regulation of MPT pores in AD progression.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is a late-onset, progressive, age-dependent
neurodegenerative disease, characterized by the progressive decline
of memory, cognitive functions, and changes in behavior and per-
sonality [1–3]. Currently, 5.4 million Americans are living with AD—
5.2 million who are 65 years of age and older, and the remaining
0.2 million under the age of 65. Current estimates are that 16 million
persons will have AD by 2050. Of Americans aged 65 years and older,
1 in 8 has AD, and nearly half of people aged 85 years and older have
the disease [4]. With lifespan increasing in humans, AD is headed
towards becoming the major health concern of elderly persons. In
addition to the personal, social, and family hardships that AD creates,
the numbers of expected AD patients will translate into extremely
high health-care costs. In 2012, the direct costs of caring for those
with AD or other dementias in the United States will total an estimat-
ed $200 billion [4].
AD is associated with the loss of synapses, synaptic dysfunction,
mitochondrial abnormalities, inﬂammatory responses, and neuronal
loss, in addition to 2 major pathological hallmarks: (1) intracellular
neuroﬁbrillary tangles and (2) extracellular amyloid beta (Aβ) depositsegon National Primate Research
h Avenue, Beaverton, OR 97006,
rights reserved.in the regions of the brain that are responsible for learning and mem-
ory. Genetic mutations in APP, PS1, and PS2 genes cause about 1–2%
of all AD cases. Several factors contribute to late-onset AD: lifestyle,
diet, environmental exposure, genetic variants in the sortilin-related
receptor 1 gene clusterin, the complement component receptor 1,
CD2AP, CD33, EPHA1, and MS4A4/MS4A6E genes and the ApoE4 geno-
type [5].
Although AD pathogenesis involves multiple molecular and cellu-
lar events, 2 events that occur early in AD development are (1) synap-
tic damage and (2) mitochondrial dysfunction [3,6–12]. These 2
events are likely caused by an age-dependent accumulation of Aβ
and phosphorylated tau in neurons [9]. Recently, several studies
reported mitochondrial abnormalities as additional molecular and
cellular events in AD progression. These events include changes in
mitochondrial DNA, decreased mitochondrial enzyme activities, ab-
normal mitochondrial gene expressions, increased mitochondrial
fragmentation, and decreased mitochondrial fusion [13]. Recently,
we reported Aβ and phosphorylated tau associated with mitochon-
drial membranes and causing mitochondrial dysfunction. Further,
we found that the mitochondrial outer membrane protein, voltage-
dependent anion channel 1 (VDAC1), directly interacts with Aβ and
phosphorylated tau, and contributes to impairments in mitochondrial
pore opening and closing [14]. The purpose of this article is to review
studies that are evaluating the role of VDAC1 in AD pathogenesis and
the relationship between VDAC1 and phosphorylated tau in mito-
chondrial dysfunction that is known to occur in AD.
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Mitochondria, present in all eukaryotic cells, including neurons, are
cytoplasmic organelles that are essential for cell survival and cell
death [15]. The half-life of neuronal mitochondria is about 1 month
[16]. Amitochondrion contains 2–10 copies ofmtDNA [15]. The number
of mtDNA copies and the number of mitochondria per cell are depen-
dent on the energy demand of the cell. Mitochondria are controlled
and regulated by mitochondrial and nuclear genomes. A mitochondrial
genome is a 16.5-kb, double-stranded circular DNAmolecule that isma-
ternally transmitted [17]. mtDNA has 2 strands: a guanine-rich outer
strand and cytosine-rich inner strand. mtDNA encodes 13 polypeptides
participating in oxidative phosphorylation. mtDNA also encodes the
12S and 16S rRNA genes. The 22 tRNA genes are required for mitochon-
drial protein synthesis. Nuclear genes encode over 1000 mitochondrial
proteins that participate in oxidative phosphorylation (OXPHOS) along
withmitochondrial-encoded genes. Nuclear mitochondrial proteins are
synthesized in the cytoplasm and are transported into mitochondria.
Mitochondria are the power houses of cells, performing several cel-
lular functions, including intracellular calcium regulation, ATP produc-
tion, the release of proteins that activate the caspase family of
proteases, and the alteration of the reduction–oxidation potential of
cells and free radical scavenging. Structurally, mitochondria are com-
partmentalized into two biolipid membranes: the inner mitochondrial
membrane and the outer mitochondrial membrane [16] (Fig. 1). The
inner mitochondrial membrane houses the ETC and provides a highly
efﬁcient barrier to the ﬂow of ions. The inner mitochondrial membrane
covers the mitochondrial matrix, which contains tricarboxylic acid and
beta-oxidation. The outer mitochondrial membrane is basically porous
and allows the passage of low molecular-weight substances, between
the cytosol and the mitochondrial intermembrane space (Fig. 2).
These mitochondrial permeability transition (MPT) pores are formed
by the mitochondrial outer membrane protein VDAC1, the mitochon-
drial inner membrane protein, the adenine nucleotide translocator
(ANT), and the matrix protein cyclophilin D (CypD).Fig. 1. The structure of mitochondria. Mitochondria are compartmentalized into two biolip
brane. The inner mitochondrial membrane houses the mitochondrial respiratory chain or el
ETC, complexes I and III leak electrons to oxygen, producing primarily superoxide radicals,
duce H2O2. Further, ETC involves the reduction of H2O2 to H2O and O2 by catalase or glutat
energy for the generation of ATP from adenosine diphosphate and inorganic phosphate.The cross talk and transport of metabolites and proteins between
mitochondria and the rest of cell are important to complete
OXPHOS and to produce mitochondrial ATP. Increasing evidence sug-
gests that mitochondrial pore opening and pore closure of VDAC are
impaired in mitochondria, in brain tissues from patients with neuro-
degenerative diseases, with inherited mitochondrial diseases, stroke,
cancer, and ischemia [18–21].
3. VDAC structure and expression
VDACs, also known as mitochondrial porins, have been found in
the outer mitochondrial membrane of paramecium tetraurelia [22]
and in the outer mitochondrial membrane of mitochondria in mam-
mals, including humans [23,24]. Studies have found that VDACs are
highly conserved [25–28]. Three isoforms of VDAC: VDAC1 and
VDAC3 are reported to have 9 exons and VDAC2, 10. The additional
exon in VDAC2 is believed to encode part of the 5′-UTR region
[29,30] (Fig. 3). VDAC1 has 2 splice variants, and VDAC2 and VDAC3
each have one splice variant.
VDAC1 is believed to be youngest of the 3 isoforms, and VDAC3,
the oldest. VDAC1/2 is estimated to have diverged from VDAC3
about 365±60 MY ago, and VDAC1 and VDAC2, about 289±63 MY
ago [31–33]. The human VDAC1 has been mapped to chromosome
5, and the human VDAC2, to chromosome 10. The mouse VDAC1
has been mapped to chromosome 11; the mouse VDAC2, to chromo-
some 14; and the mouse VDAC3, to chromosome 8. Both VDAC1 and
VDAC2 cDNA sequences in humans and mice have 90% homology, in
contrast to the VDAC3 cDNA sequences, which have 68% homology
between humans and mice (NCBI database).
Of the 3 VDAC isoforms, in mammals, VDAC1 is the most widely
expressed, followed by VDAC2 and then VDAC3 [34,35]. VDAC1 and
VDAC2 are expressed in the heart, liver, and skeletal muscles, and in
the brain. VDAC1 is also expressed, but in very low levels, in the testes
[29,30]. VDAC3 is expressed in the testes, liver, ovary, adrenal, lung,
spleen, and kidney muscles [36].id membranes: the inner mitochondrial membrane and the outer mitochondrial mem-
ectron transport chain (ETC) and provides a highly efﬁcient barrier to ionic ﬂow. In the
and superoxide radicals are dismutated by manganese superoxide dismutase and pro-
hione peroxidase accepting electrons donated by NADH and FADH2 and then yielding
Fig. 2. Schematic representation of mitochondrial permeability transition pore opening and closure. In an open state of mitochondrial permeability transition pore, metabolites,
including ADP/ATP, inorganic phosphate, pyruvate and other substrates and ions, enter and leave mitochondria after passing through the outer mitochondrial membrane. In a
closed state, VDAC does not allow the regular ﬂow of ADP/ATP through the outer membrane.
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VDAC proteins perform several important functions in the cell, in-
cluding regulating cell survival, growth, and fertility; maintaining syn-
aptic plasticity through mitochondrial permeability in the transition
pore; regulating calcium transport, regulating ATP transport, regulating
mitochondrial shape and structural changes; regulating hexokinase in-
teractions with mitochondria; and regulating apoptosis signaling
[37–39] (Fig. 4). These functions have been found to be altered in cells
from patients with neurodegenerative and mitochondrial diseases,
leading tomitochondrial dysfunction. Further, increasing evidence sug-
gests that VDAC interacts with several cytoplasmic proteins, alters
channel activity and VDAC closure and reduces VDAC channel conduc-
tance [18–21].Fig. 3. The structure of human VDAC gene. The human VDAC gene has 3 isoforms. Isoform 1
Isoform 2 and VDAC2 has 10 exonswithmultiple polyadenylation sites, and isoform 3 has 3 hasVDAC1 and VDAC2 form pores in the mitochondrial outer mem-
brane, speciﬁcally in the biolipid layers of the mitochondrial outer
membrane, and there is evidence suggesting that recombinant
VDAC3 is not able to open the pores [40]. VDACs exhibit voltage de-
pendence, and VDAC1 also closes the mitochondrial pores, when the
transmembrane voltage exceeds 20–30 mV [41,42]. In a normal and
open state of VDAC, metabolites, including ADP, ATP, inorganic phos-
phate and other substrates, enter and leave mitochondria after pass-
ing through the outer mitochondrial membrane. In a closed state,
VDAC does not allow the regular ﬂow of ADP/ATP through the outer
membrane (Fig. 2). It is believed that VDAC is constantly open in met-
abolic state. However, recent evidence suggests that VDAC closes
clearly during apoptosis in diseased neurons. Consequently, with its
pores closed, mitochondria may not be able to release ATP into theor VDAC1 has 9 exons with a start codon, ATG in exon 2 and a long polyadenylation site.
9 exons. VDAC1 has 2 splice variants, and VDAC2 and VDAC3 each have one splice variant.
Fig. 4. VDACs perform multiple functions: (1) regulating cell survival and cell growth, (2) fertility, (3) maintaining synaptic plasticity through MPT pore, (4) regulating calcium
transport, (5) regulating ATP transport, (6) regulating mitochondrial shape and structural changes, (7) regulating hexokinase interactions with mitochondria and (8) regulating
apoptosis signaling.
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ratory substrates from the cytoplasm [43,44]. The anti-apoptotic pro-
tein Bcl2-XL has been found to prevent VDAC closure [44], whereas
tBid, a pro-apoptotic member, has been found to promote the pore
closure [45]. VDAC appears to be involved in both pro- and anti-
apoptosis aspects of mitochondria.
VDAC channel conductance may be impaired in a couple different
ways. (1) In neurons from mitochondrial diseases, VDAC may interact
withmutant and cytoskeletal proteins thatmay have accumulated dur-
ing disease progression andmay have blocked themitochondrial pores.
(2) Phosphorylated VDAC may also interact with cytoplasmic proteins,
leading to the blockade of mitochondrial pores. In both scenarios, chan-
nel conductancewould be impaired andmay lead to reducedmitochon-
drial respiration and to mitochondrial dysfunction. In support of VDAC
inhibition and subsequent impairment in VDAC channel conductance
by cytoskeletal protein, tubulin, Rostovtseva and Bezrukov [46]
reported an abnormal interaction between VDAC and tubulin, resulting
in the blockage of mitochondrial pores, disruption in the ﬂux of metab-
olites betweenmitochondria and cytoplasm, and the inhibition of mito-
chondrial respiration [46]. Recently, in a study of brain tissue from
postmortem brains of patients with AD, Manczak and Reddy [14]
found that VDAC interacted with mutant AD proteins (including Aβ
and phosphorylated tau), which in turn blocked mitochondrial pores
and interrupted the ﬂow of ATP, ADP, inorganic phosphate substrates,
and respiratory substrates between mitochondria and the cytoplasm,
ultimately leading to mitochondrial dysfunction [14].
In addition, recent studies revealed that VDAC proteins and their
binding partners are modiﬁed post-translationally due to VDAC
hyperphosphorylation and are involved in the impairment of channel
conductance and malfunction of VDAC [21–48]. VDAC protein consists
ofmultiple phosphorylation sites, some of which are reported to under-
go phosphorylation [21]. VDAC1 is phosphorylated by protein kinase C,
leading to a decreased single channel current and open probability [49].
GSK3β protein phosphorylates VDAC1 at Thr51, which in turn disrupts
the binding of HK-II to VDAC [50]. Recently, Manczak and Reddy [14]
reported phosphorylated tau interacts with VDAC1, leading to pore clo-
sure and to reducedmitochondrial function in neurons from APP trans-
genic mice.
Overall, VDAC performs several functions. VDAC channel conduc-
tance is regulated by multiple factors. Further research is needed tounderstand the mechanistic links between VDAC and phosphorylated
tau and between VDAC and Aβ.5. VDAC knockout mouse models
In studies aimed at elucidating the function of VDAC proteins,
Craigen's research group generated VDAC1, VDAC2, and VDAC3 het-
erozygote (+/−) knockout embryonic stem (ES) cells and studied
them for mitochondrial respiration and mitochondrial enzymatic ac-
tivity [51]. The ES cells that were deﬁcient in VDAC1, VDAC2, and
VDAC3 were viable but showed a 30% reduction in oxygen consump-
tion and reduced cytochrome oxidase activity. The VDAC3-deﬁcient
cells did not show any change in cytochrome oxidase activity relative
to wild-type VDAC3 cells. These results indicated that each mouse
VDAC isoform is not essential for cell viability [51]. Heterozygote
knockout VDAC1, VDAC2, and VDAC3 ES cells were used to produce
both hetero- and homozygous knockout mice for VDAC1, VDAC2,
and VDAC3, but only VDAC1 and VDAC3 homozygous knockout
mice were able to be generated. Further genetic analysis revealed
that mutant and wild-type alleles of the VDAC3 locus were transmit-
ted in the expected Mendelian ratios, but VDAC1−/− mice were bred
in less-than-expected numbers, suggesting partial embryonic lethali-
ty of VDAC1−/−, in particular between embryonic days 10.5 and 11.5.
The surviving VDAC1−/− mice were fertile, but were mildly retarded
in growth, while the VDAC3−/− male mice were infertile [52].
However, the VDAC heterozygote knockout (VDAC1+/−) and
VDAC3+/− mice [52] were fertile and had a normal lifespan.
Using cell culture studies, Cheng et al. [53] studied the role of
VDAC2 in the mitochondrial pathway of apoptosis. They found BAK
complexed with VDAC2, a VDAC isoform present in low abundance
that interacts speciﬁcally with the inactive conformer of BAK. Cells
deﬁcient in VDAC2 exhibited enhanced BAK oligomerization and
were more susceptible to apoptotic death. The overexpression of
VDAC2 selectively prevented BAK activation and inhibited the mito-
chondrial apoptotic pathway. Thus, VDAC2, an isoform restricted to
mammals, may regulate the activity of BAK and may provide a con-
nection between mitochondrial physiology and the core apoptotic
pathway. Findings from this study may partially explain why VDAC2
−/− mice were not able to produce.
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pore transition, Baines et al. [49] generated simultaneous ablation of
VDAC1, VDAC2, and VDAC3 proteins by combining gene deletion
and the silencing approach. They found that mitochondria from
VDAC 1-, VDAC 3-, and VDAC 1–VDAC 3 null mice exhibited Ca2+‐
and oxidative stress-induced MPT pores that were indistinguishable
from those in wild-type mitochondria. Similarly, Ca2+‐ and
oxidative-stress-induced MPT pores and cell death were unaltered
in ﬁbroblasts lacking VDAC1, VDAC 2, VDAC 3, VDAC 1–VDAC 3, and
VDAC 1–VDAC 2–VDAC 3. Wild-type and VDAC-deﬁcient mitochon-
dria also exhibited equivalent cytochrome c release, caspase cleavage,
and cell death in response to the pro-death Bcl-2 family members Bax
and Bid. These results indicate that VDACs are critical for both MPT
and Bcl-2 family member-driven cell death.
Overall, these knockout VDAC mouse studies suggest that VDAC2
is important for cell survival, but that VDAC1 and VDAC 2 are also es-
sential for cell death, MPT pores, and mitochondrial functions, but
that cells are able to survive with a reduction in VDAC1 and VADC3.
6. Mitochondrial dysfunction in Alzheimer's disease
Mitochondrial dysfunction and synaptic damage have been identi-
ﬁed as early events in AD pathogenesis, but their underlying mecha-
nisms are not completely understood. Mitochondrial dysfunction has
been described in AD postmortem brains [54–60], AβPP transgenic
mice [61–67], and cells that express mutant APP and cells treated
with Aβ [68–77]. Recently, several groups investigated mitochondrial
gene expressions in AD postmortem brains [59,60,78–80] and in AβPP
mice [61]. They found mitochondrial-encoded genes abnormally
expressed in the brains from the AD patients and the AβPP mice.
These abnormal mitochondrial gene expressions may be compensatory
responses to mitochondrial dysfunction that Aβ may induce. Several
studies found increased free radical production, lipid peroxidation, oxi-
dative DNA and protein damages, and reduced ATP production in brains
from AD patients compared to control subjects [54–56,81–83]. In addi-
tion, studies of mitochondrial structure in AD postmortem brains and
neuronal cells expressing the mutant APP found that Aβ fragments mi-
tochondria and causes structural changes in neurons [57,60,68–71].
7. APP, Aβ and their association with mitochondria in Alzheimer's
disease
As discussed above, mitochondria dysfunction and oxidative stress
have been extensively reported. However, the precisely molecular
link between mitochondrial dysfunction and AD pathogenesis de-
scribed recently. Using biochemical, molecular, and electron micros-
copy studies, and AD postmortem brains and brains from AβPP
mice, several groups studied the connection between Aβ and mito-
chondria, and found that Aβ is associated with mitochondria and is
responsible for generating increased free radicals and mitochondrial
dysfunction [62,65–67,84–87]. Further, a recent study found that Aβ
is transported into the inner mitochondrial membrane via the
translocase of the outer membrane machinery [85].
Yan's group reported on the interaction between Aβ and the mito-
chondrial matrix proteins ABAD and CypD, which was found to lead
to increased ROS production, mitochondrial dysfunction, and cogni-
tive damage in APP mice (J20 line) [62–84]. They also found reduced
interaction between Aβ and ABAD, and between Aβ and CypD. They
found that reduced ABAD and CypD protects against Aβ toxicity in
AD neurons [84,88].
Several studies found APP in mitochondrial membranes, in neu-
rons affected by AD [55,89–91]. These studies also found mitochon-
drial APP in the N-terminal, inside the mitochondria, and in the
C-terminal of the protein that faces the cytosolic side [89,91]. Recent-
ly, Devi and colleagues found that full-length APP and the C-terminal
truncated APP without the Aβ domain accumulate progressively inmitochondria, in patients with mild, moderate, and severe AD, but
not in age-matched subjects without AD [55].
Overall, these studies suggest that APP and Aβ are associated with
mitochondrial membranes and are critically involved in mitochondri-
al dysfunction and neuronal damage in AD progression.
8. Phosphorylated tau and its association with mitochondria in
Alzheimer's disease
Several groups recently investigated the relationship between tau
and mitochondria, and found that N-terminal tau is associated with
mitochondrial membranes [92–94]. Amadoro et al. [92] reported
that a 20–22 kDa NH2-truncated tau fragment was largely enriched
in human mitochondria from synaptosomes of AD brains and that
the amount of tau in the terminal ﬁelds correlated with pathological
synaptic changes and with organelle functional impairment.
Atlante et al. [93] studied the relationship between overexpressed
N-terminal tau fragments (1–25 aa and 26–44 aa) and mitochondrial
dysfunction. They tested both fragments for ATP synthesis, mem-
brane potential and ANT activity. They found that oxidative phos-
phorylation was not affected by the N-terminal fragment 1–25 aa
tau fragment, but was dramatically impaired by the N-terminal
26–44 aa tau fragment. Both cytochrome c oxidase and the ANT are
targets of the N-terminal 26–44 tau fragment, but the ANT is a unique
mitochondrial target, responsible for impairment of oxidative phos-
phorylation by the N-terminal 26–44 tau fragment, which exerts del-
eterious effects on cellular availability of ATP when the ATP is
synthesized in the inner mitochondrial membrane.
Quintanilla et al. [94] reported that the expression of tau that they
induced at Asp-421 to mimic caspase cleavage (T4C3) was toxic to
immortalized cortical neurons compared with a full-length tau
isoform (T4). T4C-expressing cells induced mitochondrial fragmenta-
tion and elevated oxidative stress levels, in comparison with
T4-expressing cells. Thapsigargin treatment of T4 or T4C3 cells,
which causes an increase in intracellular calcium levels, resulted in
a signiﬁcant decrease in mitochondrial potential. It also resulted in
the loss of mitochondrial membrane integrity in T4C3 cells when
compared with cells expressing T4. Mitochondrial fragmentation
and membrane damage were ameliorated in T4C3 cells when they
were pretreated with cyclosporine A or FK506, indicating that the
calcium-dependent phosphatase calcineurin in these pathogenic
events.
Overall, ﬁndings from these studies suggest that the N-terminal
fragment of tau may cause mitochondrial dysfunction and defects in
oxidative phosphorylation, in AD neurons.
9. Elevated VDAC1 levels in AD brains and AD transgenic mice
To our knowledge, very little published evidence is available ad-
dressing the involvement of VDAC1 in the progression of disease in
AD. To determine the role of VDAC1 in AD progression and pathogen-
esis, using quantitative real-time RT–PCR with Sybr-Green chemistry,
we measured mRNA fold changes for VADC1 in postmortem brain
specimens from patients in early and late stages of AD and in post-
mortem brain specimens from patients without AD [65]. Increased
mRNA expression was found in AD brains relative to brains from con-
trol subjects. Further, using immunoblotting analysis and quantitative
densitometry, VDAC1 protein levels were quantiﬁed in frontal cortical
tissues from all AD patients and control subjects. Signiﬁcantly in-
creased VDAC1 was found in AD patients relative to control subjects
[14]. These ﬁndings suggest that VDAC1 levels progressively increase
as AD progresses and may be implicated in AD progression.
To determine whether VDAC1 increases with age in Aβ-
overexpressed APP transgenic mice, we also quantiﬁed VDAC1 pro-
tein levels in cerebral cortex tissues from 6-, 12-, and 24-month
APP mice and age-matched non-transgenic wild-type mice. We
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24-month-old APP mice, relative to the 6-month-old APP mice, indi-
cating an age-dependent increase of VDAC1 in the cerebral cortex of
APP mice. To determine whether mutant APP and/or Aβ elevates
VDAC1, we compared VDAC1 immunoblotting and densitometry
data with VDAC1 data from the wild-type mice. We found signiﬁ-
cantly increased levels of VDAC1 in the 6- and 12-month-old APP
mice, relative to the 6- and 12-month-old non-transgenic wild-
type mice. To determine if aging plays a role in VDAC1 expression,
we compared immunoblotting data from the 6-, 12-, and
24-month-old wild-type mice. We found signiﬁcantly increased
levels of VDAC1 in the 12- and 24-month-old non-transgenic
wild-type mice, relative to 6-month-old wild-type mice, indicating
an age-dependent increase in VDAC1, in the cerebral cortex of the
wild-type mice.
Ren and colleagues [95] studied the effect of the Aβ peptide 25–35
on mitochondrial structure and function and on the expression of
proteins associated with the mitochondrial permeability transition
pore in rat hippocampal neurons. They injected Aβ peptide into hip-
pocampal area CA1. Normal saline was injected as a control to assess
the hippocampal structure by transmission electron microscopy.
ATPase activity, intracellular Ca2+, and mitochondrial membrane po-
tential were measured. The expression of genes associated with the
MPTP, including VDAC1, ANT, and CypD, were evaluated. They
found that the Aβ injection damaged the mitochondrial structure of
hippocampal neurons, decreased ATPase activity and mitochondrial
membrane potential, and increased intracellular Ca2+. The expres-
sion levels for VDAC, ANT, and CypD in all groups were signiﬁcantly
higher than those in the normal control group injected after Aβ25–
35 peptide. These results indicate that Aβ25–35 damages mitochon-
dria in rat hippocampal neurons and affects mitochondrial dysfunc-
tion, as well as increases the expression of genes associated with
MPT pores. Mitochondrial dysfunction may result in increased MPTP
gene expression, leading to neurodegenerative effects.
Cuadrado-Tejedor and colleagues [96] studied whether VDAC1 is
involved in the release of apoptotic proteins in AD. Through proteo-
mic analysis followed by immunoblotting blotting and immunohisto-
chemical analyses, they found that VDAC1 is overexpressed in the
hippocampus from amyloidogenic AD transgenic mice. VDAC1 was
also overexpressed in postmortem brain tissue from AD patients at
an advanced stage of disease progression. Interestingly, Aβ soluble
oligomers were able to induce the up-regulation of VDAC1 in a
human neuroblastoma cell line, further supporting a correlation be-
tween Aβ levels and VDAC1 expression. In hippocampal extracts
from transgenic mice, a signiﬁcant increase was observed in the
level of VDAC1 that was phosphorylated at an epitope susceptible to
phosphorylation by glycogen synthase kinase-3β, whose activity
was also increased. The levels of hexokinase I (HXK1), which interacts
with VDAC1 and affects its function, were decreased in mitochondrial
samples from AD models, indicating that reduced HXKI levels favor a
VDAC1 involvement in disease progression of AD [96].
Overall, these studies suggest that VDAC1 increases with the pro-
gression of AD. Further, VDAC1 also increases in an age-dependent
manner, likely an important factor in better understanding AD
progression.
10. Elevated VDAC1 and its interaction with Aβ in neurons from
AD tissues
As discussed above, in AD neurons, we found large amounts of Aβ
associated with the outer mitochondrial membrane [65]. Further, to
determine if Aβ is associated with outer mitochondrial membrane,
immunoprecipitation analysis was conducted, using cortical protein
lysates from brains of AD patients at different stages of disease pro-
gression, and from brains of APP and APP/PS1 transgenic mice and
of age-matched wild-type mice. These histologic studies involvedthe use of Aβ (6E10 monoclonal A11 oligomeric Aβ) and VDAC1 anti-
bodies [14]. A 4 kDa Aβ and a 100 kDa full-length APP were found in
VDAC1 immunoprecipitation elutes from deﬁnite and severe AD pa-
tients and from 20-month-old APP and APP/PS1 mice. Similar to mo-
nomeric Aβ, oligomeric Aβ was also found in immunoprecipitation
elutes from deﬁnite and severe AD patients and from APP and APP/
PS1 mice. Findings from these studies clearly suggest that both mono-
meric and oligomeric Aβ interact with VDAC1 and blocks the mito-
chondrial pores, interrupting the transport of metabolites and
proteins between mitochondria and the rest of the cell.
Thinnes [97] proposed that GxxxG motif of N-terminal part of
VDAC1 might interact with GxxxGmotif of C‐terminal part of Aβ pep-
tide. The GxxxGmotifs are established as aggregation/membrane per-
turbation motifs. Aβ, a C-terminal cleaved product from APP by
beta-secretase BACE1 and gamma-secretase, has been insinuated to
induce AD via apoptosis by opening type-1 porin/VDAC in cell mem-
branes of hypometabolic neuronal cells. Considering the ubiquitous
expression modus of APP, beta- and gamma-secretases and type-1
VDAC/eukaryotic porin a basic model of apoptosis might be given.
Ramírez and colleagues [98] studied VDACs involvement in AD
pathogenesis using affected regions, including frontal cortex and hip-
pocampus, from AD patients and controls subjects. They found
pl-VDAC and mERα present in the caveolae tissues from the human
cortex and hippocampus, in a complex with scaffolding caveolin-1
which likely provides mERα stability at the plasma membrane. In
AD brains, VDAC was accumulated in the caveolae and in dystrophic
neurites of senile plaques, whereas mERα was expressed in astro-
cytes surrounding the plaques. Together with previous data on mu-
rine neurons demonstrating the participation of pl-VDAC in
Aβ-induced neurotoxicity, Ramírez et al. data suggest that the mito-
chondrial channel may be involved in membrane dysfunction similar
to that observed in AD neuropathology.
Overall, ﬁndings from these studies suggest that VDAC1 normally
interacts with Aβ, and this abnormal interaction increases with AD
progression. Further, there is evidence to support pl-VDAC being
linked with the caveolae of the cortex and hippocampus, and that
VDAC1 is heavily localized in dystrophic neurites of senile plaques.
11. Elevated VDAC1 and its interaction with phosphorylated tau in
Alzheimer's disease
A physiological link between abnormal and phosphorylated tau,
and mitochondrial dysfunction has been proposed in AD [99],
suggesting that VADC1 may be associated with mitochondrial dys-
function found in AD. Researchers reported N-terminal tau associated
with mitochondria in brain tissues from AD patients and AD mouse
models. To determine whether phosphorylated tau interacts with
VDAC1, we conducted immunoprecipitation analysis, using cortical
protein lysates from the brains of AD patients and of control subjects,
and APP/PS1, 3xTg.AD in brain tissues from transgenic mice and
age-matched wild-type mice. We found a 32-kDa band of VDAC1 in
the phosphorylated tau immunoprecipitation elutes in the brains
from AD patients and from APP/PS1, 3xTg.AD transgenic mice. These
results were cross-checked using a VDAC1 antibody for immunopre-
cipitation and a phosphorylated tau antibody for immunoblotting.
We found a 60 kDa band of phosphorylated tau protein in the
VDAC1-immunoprecipitation elutes, in the brain tissue from AD pa-
tients and from APP/PS1, 3xTg.AD transgenic mice. These ﬁndings
suggest that phosphorylated tau interacts with VDAC1. These obser-
vations were further conﬁrmed by double-labeling immunoﬂuores-
cence analyses of VDAC1 and phosphorylated tau in brain tissues
from AD patients and 3XTg.AD mice.
Overall, the results from our study suggest that VDAC1 interacts
with phosphorylated tau in AD neurons and that these interactions
increase with disease progression. The VDAC1-phosphorylated tau
complexes block mitochondrial pores, interrupt the ﬂux of
73P.H. Reddy / Biochimica et Biophysica Acta 1832 (2013) 67–75metabolites between mitochondrial membranes and cytoplasm, and
impair the gating of VDAC channel, leading to mitochondrial dysfunc-
tion and neuronal damage in AD neurons.
12. Conclusions and future directions
A large body of evidence suggests that mitochondrial dysfunction
and oxidative stress are involved in AD progression and pathogenesis.
Further, recent research on AD postmortem brains, brain tissues from
AD mouse models, and cells that express Aβ and phosphorylated tau
revealed that Aβ and phosphorylated tau are associated with mito-
chondria, resulting in mitochondrial dysfunction and synaptic dam-
age in AD-affected neurons. More speciﬁcally, several recent studies
found Aβ interacting with the mitochondrial matrix proteins CypD
and ABAD, and that this interaction leads to increased ROS production
and mitochondrial dysfunction. In addition, recent research from the
Reddy lab, that used postmortem brain tissues from AD patients and
tissues from AD mouse models, revealed that in the mitochondrial
outer membrane protein, VDAC1 interacts with both Aβ and phos-
phorylated tau, resulting in the blockage of MPT pores and a
disruption in the transport of proteins and metabolites between mi-
tochondria and the rest of cell. Results from this study also showed
that VDAC1 likely causes defects in oxidative phosphorylation and
mitochondrial dysfunction in AD neurons. It is well-established that
MPT pores are formed by VDAC1, ANT and CypD. Proper maintenance
of pore opening and pore closure in mitochondria is critical for the
transport of metabolites – including ADP, inorganic phosphorous,
ATP, and proteins – from the cytoplasm to the mitochondria and
vice versa. However, as described earlier, in the mitochondrial matrix,
CypD is elevated, it interacts with Aβ in AD neurons, and may cause
mitochondrial structural and functional abnormalities. Further, hip-
pocampal neurons treated with Aβ exhibited elevated levels of the
pore forming proteins VDAC1, CypD and ANT, and they revealed al-
tered mitochondrial membrane potential and altered intracellular
Ca2+ levels.
Elevated levels of VDAC1 were found in postmortem brain tissues
from AD brains and AD transgenic mice, and evidence indicating an
interaction between VDAC1 and Aβ and between VDAC1 and phos-
phorylated tau was found in both brain tissues [14]. Complexes of
VDAC1–Aβ and VDAC1–phosphorylated tau may be involved in the
blockage of mitochondrial pores, leading to the interruption of mito-
chondrial protein and metabolite transport, and to the impairment of
VDAC channel conductance. In turn, these changes may lead to mito-
chondrial dysfunction in AD neurons. Based on these observations, re-
duced levels of VDAC1, Aβ, and phosphorylated tau may reduce the
interactions between VDAC1 and Aβ, and between VDAC1 and phos-
phorylated tau in AD neurons, resulting in the maintenance of normal
mitochondrial pore opening and pore closure, ultimately leading to
mitochondria supplying ATP to nerve terminals (as is the case in
healthy neurons). If these hypotheses hold, then reduced interaction
between VDAC1 and Aβ and phosphorylated tau may prove useful
in boosting synaptic and cognitive functions in AD.
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